Brilinta Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
A timeline chronicling the development history of AstraZeneca’s ticagrelor.
You may also be interested in...
The consistency of numerous analyses supporting a negative interaction between ticagrelor and high-dose aspirin, as used in the U.S., helped overcome FDA’s initial reluctance to approve AstraZeneca’s platelet inhibitor without a new trial.
FDA’s review of AstraZeneca’s platelet inhibitor ticagrelor was tinged by the agency’s earlier evaluation and delayed approval of Lilly/Daiichi’s prasugrel for acute coronary syndromes.
FDA staff that participated in the review of AstraZeneca’s anticoagulant.